T 2963/19 (Liposomal irinotecan/IPSEN) of 18.03.2022

European Case Law Identifier: ECLI:EP:BA:2022:T296319.20220318
Date of decision: 18 March 2022
Case number: T 2963/19
Petition for review of: -
Application number: 13731230.2
IPC class: A61K 31/517 A61P 35/00 A61K 9/00 A61K 31/4745 A61K 31/513
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN
Applicant name: Ipsen Biopharm Ltd.
Opponent name: Teva Pharmaceutical Industries Ltd
Board: 3.3.07
Headnote: -
Relevant legal provisions: European Patent Convention Art 56 European Patent Convention Art 83 European Patent Convention Art 87(1)
Keywords: Priority - same invention (no)
Sufficiency of disclosure - plausibility (yes)
Inventive step - (no)
Inventive step - closest prior art
Inventive step - reasonable expectation of success of clinical trial
Catchword: -
Cited cases: T 2506/12 T 2154/14 T 0239/16 T 0116/18 T 0096/20
Citing cases: G 0002/21 T 1437/21 T 1941/21 T 0122/23 T 0136/24

Order

For these reasons it is decided that:

The appeal is dismissed.